IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis

被引：175

作者：

Siersbaek, Rasmus ^{[1
,10
]}

Scabia, Valentina ^{[2
]}

Nagarajan, Sankari ^{[1
]}

Chernukhin, Igor ^{[1
]}

Papachristou, Evangelia K. ^{[1
]}

Broome, Rebecca ^{[1
]}

Johnston, Simon J. ^{[3
,11
]}

Joosten, Stacey Ep ^{[4
]}

Green, Andrew R. ^{[3
]}

Kumar, Sanjeev ^{[1
,5
]}

Jones, Julia ^{[1
]}

Omarjee, Soleilmane ^{[1
]}

Alvarez-Fernandez, Ruben ^{[1
]}

Glont, Silvia ^{[1
]}

Aitken, Sarah J. ^{[1
,6
,7
]}

Kishore, Kamal ^{[1
]}

Cheeseman, Danya ^{[1
]}

Rakha, Emad A. ^{[3
]}

D'Santos, Clive ^{[1
]}

Zwart, Wilbert ^{[4
,8
,9
]}

Russell, Alasdair ^{[1
]}

Brisken, Cathrin ^{[2
]}

Carroll, Jason S. ^{[1
]}

机构：

[1] Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge CB2 ORE, England

[2] Ecole Polytech Fed Lausanne EPFL, ISREC Swiss Inst Expt Canc Res, Sch Life Sci, CH-1015 Lausanne, Switzerland

[3] Univ Nottingham, Nottingham Breast Canc Res Ctr, Sch Med, Div Canc & Stem Cells,Biodiscovery Inst, Univ Pk, Nottingham NG7 2RD, England

[4] Netherlands Canc Inst, Oncode Inst, Div Oncogen, Amsterdam, Netherlands

[5] Addenbrookes Hosp, Cambridge CB2 0QQ, England

[6] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Dept Histopathol, Cambridge CB2 0QQ, England

[7] Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England

[8] Eindhoven Univ Technol, Dept Biomed Engn, Lab Chem Biol, Eindhoven, Netherlands

[9] Eindhoven Univ Technol, Dept Biomed Engn, Inst Complex Mol Syst, Eindhoven, Netherlands

[10] Univ Southern Denmark, Campusvej 55, DK-5230 Odense M, Denmark

[11] AstraZeneca, Translat Med, Cambridge CB2 0AA, England

来源：

CANCER CELL | 2020年 / 38卷 / 03期

基金：

英国惠康基金;

关键词：

ENDOTHELIAL GROWTH-FACTOR; ER-ALPHA; INTERLEUKIN-6; IL-6; STAT3; TRANSCRIPTION; DETERMINANT; RESISTANCE; CYTOKINE; DATABASE;

D O I：

10.1016/j.ccell.2020.06.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The cytokine interleukin-6 (IL6) and its downstream effector STAT3 constitute a key oncogenic pathway, which has been thought to be functionally connected to estrogen receptor alpha (ER) in breast cancer. We demonstrate that IL6/STAT3 signaling drives metastasis in ER+ breast cancer independent of ER. STAT3 hijacks a subset of ER enhancers to drive a distinct transcriptional program. Although these enhancers are shared by both STAT3 and ER, IL6/STAT3 activity is refractory to standard ER-targeted therapies. Instead, inhibition of STAT3 activity using the JAK inhibitor ruxolitinib decreases breast cancer invasion in vivo, Therefore, IL6/STAT3 and ER oncogenic pathways are functionally decoupled, highlighting the potential of IL6/STAT3-targeted therapies in ER+ breast cancer.

引用

页码：412 / +

页数：21

共 50 条

[1] IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment
Manore, Sara G.
Doheny, Daniel L.
Wong, Grace L.
Lo, Hui-Wen
FRONTIERS IN ONCOLOGY, 2022, 12
[2] Mammary adipocytes drive breast tumor progression and angiogenesis via the VEGF/IL6/STAT3 signaling axis
Roy, Roopali
Shimura, Takaya
Merritt, Lauren
Gonzalez, Katherine
Man, Emily
Lotz-Bousvaros, Margaret
Pories, Susan
Moses, Marsha A.
CANCER RESEARCH, 2020, 80 (16)
[3] Opioids drive breast cancer metastasis through the δ-opioid receptor and oncogenic STAT3
Tripolt, Sabrina
Neubauer, Heidi A.
Knab, Vanessa M.
Elmer, Dominik P.
Aberger, Fritz
Moriggl, Richard
Fux, Daniela A.
NEOPLASIA, 2021, 23 (02): : 270 - 279
[4] AT7519 against lung cancer via the IL6/STAT3 signaling pathway
Zhou, Feng
Zhu, Fanyun
Zhu, Tianru
Zhao, Zhucheng
Li, Luyao
Lin, Shichong
Zhao, Haiyang
Yang, Lehe
Zhao, Chengguang
Wang, Liangxing
Li, Jifa
Huang, Xiaoying
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2022, 609 : 31 - 38
[5] Targeting Tumor-Stromal IL6/STAT3 Signaling through IL1 Receptor Inhibition in Pancreatic Cancer
Dosch, Austin R.
Singh, Samara
Dai, Xizi
Mehra, Siddharth
Silva, Iago De Castro
Bianchi, Anna
Srinivasan, Supriya
Gao, Zhen
Ban, Yuguang
Chen, Xi
Banerjee, Sulagna
Nagathihalli, Nagaraj S.
Datta, Jashodeep
Merchant, Nipun B.
MOLECULAR CANCER THERAPEUTICS, 2021, 20 (11) : 2280 - 2290
[6] Resistance to Anti-VEGF Therapy Mediated by Autocrine IL6/STAT3 Signaling and Overcome by IL6 Blockade
Eichten, Alexandra
Su, Jia
Adler, Alexander P.
Zhang, Li
Ioffe, Ella
Parveen, Asma A.
Yancopoulos, George D.
Rudge, John
Lowy, Israel
Lin, Hsin Chieh
MacDonald, Douglas
Daly, Christopher
Duan, Xunbao
Thurston, Gavin
CANCER RESEARCH, 2016, 76 (08) : 2327 - 2339
[7] Targeting the IL-6/STAT3 Signalling Cascade to Reverse Tamoxifen Resistance in Estrogen Receptor Positive Breast Cancer
Tsoi, Ho
Man, Ellen P. S.
Chau, Ka Man
Khoo, Ui-Soon
CANCERS, 2021, 13 (07)
[8] IL6/STAT3 Signaling Orchestrates Premetastatic Niche Formation and Immunosuppressive Traits in Lung
Jing, Bo
Wang, Tong
Sun, Beibei
Xu, Jianhua
Xu, Dongliang
Liao, Yueling
Song, Hongyong
Guo, Wenzheng
Li, Kaimi
Hu, Min
Zhang, Siwei
Ling, Jing
Kuang, Yanbin
Zhang, Tuo
Zhou, Binhua P.
Yao, Feng
Deng, Jiong
CANCER RESEARCH, 2020, 80 (04) : 784 - 797
[9] Autocrine IL6/STAT3 Signaling Enhances Survival of Chronic Lymphocytic Leukaemia Cells
Liu, Fengting
Jia, Li
Farren, Timothy
Gribben, John G.
Agrawal, Samir
BLOOD, 2010, 116 (21) : 1481 - 1481
[10] The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer
Chandra Sekhar Amara
Karthik Reddy Kami Reddy
Yang Yuntao
Yuen San Chan
Danthasinghe Waduge Badrajee Piyarathna
Lacey Elizabeth Dobrolecki
David J. H. Shih
Zhongcheng Shi
Jun Xu
Shixia Huang
Matthew J. Ellis
Andrea B. Apolo
Leomar Y. Ballester
Jianjun Gao
Donna E. Hansel
Yair Lotan
H. Courtney Hodges
Seth P. Lerner
Chad J. Creighton
Arun Sreekumar
W. Jim Zheng
Pavlos Msaouel
Shyam M. Kavuri
Nagireddy Putluri
Nature Communications, 15

← 1 2 3 4 5 →